Begin deliveries of CYFENDUS™ vaccine
Delivered by the deadline
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 28 Nov 2023
- Due
- 31 Dec 2023
- Delivered
- Q4 2023
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Deliveries are expected to begin this calendar year”
What we found
Evidence strength A What the grades mean
Emergent began CYFENDUS deliveries under the November 2023 contract by end of 2023; Q4 2023 earnings confirm sales revenue recorded.
-
A Emergent BioSolutions Receives U.S. FDA Approval of CYFENDUS™
“Emergent has been delivering CYFENDUS™ vaccine to the U.S. Department of Health and Human Services since 2019” ✓ confirmed on the page
-
A Emergent BioSolutions Receives $75 Million Contract Option
“Deliveries are expected to begin this calendar year” ✓ confirmed on the page
-
B EMERGENT BIOSOLUTIONS REPORTS FOURTH QUARTER 2023 FINANCIAL RESULTS
“higher sales of CYFENDUS®, Anthrasil® and BioThrax®”
Checked 4 Oct 2026.
Commitment lineage
Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.
- Deadline drift +821 days
- 3 versions
-
Version 1 · original · stated 28 Nov 2023
Deadline 31 Dec 2023 (“this calendar year”) · wording expected
-
Version 2 · stated 5 Sep 2025
Deadline 31 Dec 2025 (“this calendar year”) · wording expected
“Deliveries are expected to begin this calendar year”
-
Version 3 · stated 5 Sep 2025
Deadline 31 Mar 2026 (“by March 2026”) · wording expected
“Deliveries are expected to begin this calendar year and are scheduled to be completed by March 2026.”
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Production start
- Indicative materiality
- High rules
- Action
- Begin
- Deliverable
- CYFENDUS™ vaccine doses
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
- Depends on
- Customer
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: disagreesGemini (Google) re-read the evidence blind and read it as “no_evidence”.
- Tie-breakA stronger model read the evidence and both earlier answers, without knowing which was recorded, and agrees with the second check.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you Emergent BioSolutions Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2023-EBS-002487 · Corrections policy